- Home
- SEED vs VIVS Comparison
SEED vs VIVS Comparison
Compare SEED & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEED | VIVS |
|---|---|---|
| Founded | 1997 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7M | 8.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SEED | VIVS |
|---|---|---|
| Price | $1.56 | $2.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 43.1K | ★ 46.0K |
| Earning Date | 06-26-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,910,081.00 | $140,000.00 |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 35.92 |
| 52 Week Low | $0.74 | $1.41 |
| 52 Week High | $2.70 | $21.96 |
Technical Indicators
Market Signals| Indicator | SEED | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 58.13 | 49.83 |
| Support Level | $1.25 | $2.11 |
| Resistance Level | $1.46 | $2.40 |
| Average True Range (ATR) | 0.11 | 0.13 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 97.48 | 54.92 |
Price Performance
Historical ComparisonAbout SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.